<DOC>
	<DOCNO>NCT02621541</DOCNO>
	<brief_summary>Predicting aggressive behavior group nonfunctional pancreatic neuroendocrine tumor ( NF P-NET ) remain difficult problem clinical practice . At present , treatment plan P-NET significantly restrict limited result conventional imaging . In addition , increase use multidetector compute tomography ( MDCT ) magnetic resonance imaging ( MRI ) increase number NF P-NETs detect . Somatostatin receptor scintigraphy ( SRS ) combine anatomical imaging conventional modality image P-NET , method diagnostic accuracy still remain compromised . Furthermore , recently encourage result obtain P-NET use 68Ga-labelled somatostatin analog , DOTA-1-NaI3-octreotide ( 68Ga-DOTANOC ) positron emission tomography-computed tomography ( PET-CT ) . The aim current project evaluate possibility enhance diagnostic accuracy use dual trace functional image 18F-labelled fluorodeoxyglucose ( 18F-FDG ) 68Ga-DOTANOC PET-CT imaging patient NF P-NET . The study consist 20 patient NF P-NET . The patient enrol study image 68Ga-DOTANOC 18F-FDG PET-CT follow surgery follow-up endoscopic ultrasonography ( EUS ) biopsy . The data collect autumn 2015 spring 2018 .</brief_summary>
	<brief_title>Nonfunctional Pancreatic NET PET Imaging</brief_title>
	<detailed_description />
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<criteria>suspicion nonfunctional PNET primary CT ( i.e hypervascularity ) MRI sign informed consent vulnerable study subject describe Finnish law concern clinical study ( disable , child , pregnant breastfeed woman , prisoner ) include .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>neuroendocrine tumor</keyword>
	<keyword>pancreas</keyword>
	<keyword>diagnosis</keyword>
	<keyword>positron emission tomography</keyword>
</DOC>